September 21, 2026 · Patent expires June 24, 2028

Jakafi (Ruxolitinib): The 2028 Generic Opportunity Window

Incyte Corporation's Jakafi (ruxolitinib phosphate) generated $2.8 billion in full-year 2024 U.S. net product revenue and anchors a $4.5 billion global franchise. With zero generic versions commercially available in the United States today, the market remains 100% brand-only. Core composition-of-matter patent US 7,598,257 runs through June 24, 2028, inclusive of pediatric exclusivity. Leading Indian generic manufacturers including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, and Natco Pharma have filed Paragraph IV ANDAs positioning for entry.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.